

SENJU

COMPANY PROFILE



# President's Message

---

The characters that comprise Senju's company name in the Japanese language are “Sen” and “Ju”, which literally mean “thousand” and “bringing happiness”, respectively. Senju, bringing much (a thousand) happiness, has an objective to bring a “happiness” to the people associated with us through the development of original pharmaceutical products for the care of the five senses (eyes, ears, nose, throat and skin), which ultimately improves the joy of living.

This is our management policy; “Good Company”.

We strongly believe that Senju should be a trustworthy and essential company by putting ourselves into the other person's shoes and acting under the Action Guideline; “If I were you”.

Yukoh Yoshida  
President & CEO





## Management Policy

### Good Company

**At Senju Pharmaceutical, our mission is to pursue happiness for every person associated with the company.**

"Being a good company" is our management policy.

As a company that aims to be reliable, necessary, and valuable to society, we are committed to pursuing happiness for all people associated with the company, rather than simply becoming a "Big Company" that pursues only greater growth and increased sales.

## Action Guideline

### If I were you

#### "If I were you"

Considering others' viewpoints is the starting point for all of our business activities. We should not do to others what we would not like to be done to us.

To treat others in a way that would make us happy if we were treated that way, we need to think about and do things from others' points of view at all times.

These are the action guidelines that Senju Pharmaceutical employees aim to follow.

## SENJU SENSE

SENJU SENSE is a systematic collection of the concepts and values that have been carefully handed down over the generations since the founding of our company, including our Management Policy "Good Company". It is a collective name for Senju's values, which are so essential during decision-making and the execution of our responsibilities. By ensuring that each and every employee shares our SENJU SENSE and works with firm belief in the pursuit of happiness for all people associated with the company, we aim to come up with a variety of innovative new ideas, thereby ensuring that Senju remains a "Good Company".

# Ethical Products for Medical Professionals

As a manufacturer of ophthalmological drugs, Senju Pharmaceutical has entered the promising fields on the front lines of medicine.



In addition to creating new medicines, particularly ophthalmic solutions in the field of eye medicine, Senju Pharmaceutical offers a broad range of generic products and we steadily implement measures to respond to changes in the market environment. What's more, we also work hard to develop and promote what's referred to as "orphan drugs", which treat rare diseases suffered by extremely small numbers of patients.

Senju Pharmaceutical will take on new challenges every day with the aim of "maintaining and improving vision" for as many patients as possible by increasing the added value of our products by strengthening the information gathering and communication capabilities we have built up over many years in the field of ophthalmology and by accurately identifying treatment needs in the medical workplace as well as by enhancing our marketing, sales and logistics functions for promoting activities to encourage the rapid popularization of our products.



# M M S (Medical Management Supporter)

For Human, for Medical, for Tomorrow.



Senju Pharmaceutical has developed an MMS (Medial Management Supporter) business to provide various types of support for the operation of eye clinics with the aim of contributing to healthcare in local communities.

Strong clinic management is essential to providing high-quality health-care.

Through MMS we provide support to the many management challenges faced by ophthalmologists, including the handling of reforms to various systems, labor management, the fostering of human resources, the handling of tax issues, building partnerships with other facilities, and improving patient satisfaction.

What's more, in order to provide ever-changing healthcare information to ophthalmologists on a timely basis, we provide information via management magazine Medi-Net and our ophthalmologists' management information service website.



Management magazine Medi-Net



Architectural models

# Over the Counter (OTC) Products

The Mytear brand was developed from our research into tears.



Tears are invaluable to our eyes and they have even been described as “heaven’s eye medicine”. Thanks to our ongoing efforts in tear research, in 1965 Senju Pharmaceutical launched Japan’s first ever tear-type eye medicine, the artificial tear Mytear.

Fifteen years later in 1980 we launched Mytear CL as a contact lens use eye medicine, the first in Japan that could be applied while still wearing soft contact lenses. We have continued to develop eye medicine under the Mytear brand in response to changing times and changing user needs.

In recent years, we have utilized our product development capabilities as a manufacturer of prescription eye medicine and our many years of marketing experience to launch unique and high quality products, including Mytear EYETECT, which

is an over-the-counter product containing pranoprofen, a nonsteroidal anti-inflammatory drug that has been recognized as an effective and safe prescription product.



# Overseas Activities

When it comes to eye health and the development of pharmaceutical products, there are no national borders.



Senju Pharmaceutical promotes international activities with an eye on the pharmaceutical products of tomorrow, beyond the limits of individual countries or companies.

As we approach the global age, Senju Pharmaceutical's overseas activities have become more diverse than ever. We have promoted the export of finished products, new product technology and patent derivations, and we are now active in more than 50 countries. In order to build partnerships and introduce the latest technologies and information as quickly as possible, it is necessary to remain unconstrained by regional location, industry or scale. In the United States, we have established a subsidiary SENJU USA, INC. with the aim of promoting research and development in United States pharmaceutical products. In China, we have established subsidiary SENJU PHARMACEUTICAL

SCIENCE & TECHNOLOGY (BEIJING) CO., LTD. and local manufacturing and sales company SENJU WANHE PHARMACEUTICAL (SHENZHEN) CO., LTD. We are actively seeking to expand the scope of our activities and have established local offices in Russia and Vietnam.



# Research and Development

We are using our cutting edge technology and unique research system to pursue the limitless possibilities of people and science.



“All things in nature have a reason for being. Today’s common sense is not common sense tomorrow.” This is the motto of our researchers. Senju Pharmaceutical pursues research and development through flexible thinking without being constrained by existing limits or stereotypes through our unique research system, which includes international joint research projects and collaborative research with industry and academia. At the Senju Laboratory of Ocular Science and our Oregon Laboratory in the United States, we carry out basic

research into the creation of treatments by using cutting edge technology to identify the molecules that cause eye diseases. At our Kobe Creative Center, we promote research that will lead directly to product development, including accumulating the data needed for the approval of pharmaceutical products. All of our centers work in close cooperation on this research. Our eyes are fixed firmly on the future. Our goal and aspiration is to develop the pharmaceutical products that are truly needed by society, safely and as quickly as possible.


■ Kobe Creative Center



■ Senju Laboratory of Ocular Science



■ Oregon Laboratory, United States





# Production

Bringing you high quality pharmaceutical products from factories that meet PIC/S GMP standards



When manufacturing pharmaceutical products, it is essential to comply with the GMP (Good Manufacturing Practice) standard for the manufacture of pharmaceutical products and quasi drugs, from delivery of raw materials through to shipment of the finished product.

What's more, because eye medicine is a sterile product, there is a need for sterile manufacturing facilities that guarantee a high level of sterility, and a need for the installation of testing equipment and quality control.

Senju Pharmaceutical works to comply with PIC/S-GMP

standards at an early stage in anticipation of revisions to GMP standards. Moreover, we have built a system that allows us to implement ongoing improvements to reduce our impact on the environment.

We will continue to deliver a steady supply of high quality pharmaceutical products to Japan and the world from factories that combine state-of-the-art manufacturing facilities with a state-of-the-art manufacturing environment.

PIC/S: The Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme

## Manufacturing Plant Karatsu



## Manufacturing Plant Fukusaki



Status of ISO14001 Certification Acquisition : Plant Fukusaki in December 2007 / Plant Karatsu in December 2014

# Animal Health

Using the pharmaceutical technologies developed for humans to develop health products for companion animals



People are not the only living things to use sense organs such as the eyes and ears to collect abundant information for use in their everyday lives. Sense organs are also an essential part of the daily lives of the pets who live side by side with humans. In recent years, improved living standards and medical advances have increased the length of time that pets and humans can live side by side, leading to increased risk from ageing associated lifestyle diseases and increased importance of the sense organs in pets' daily lives. Senju Pharmaceutical has continued to utilize the pharmaceutical development technologies we have accumulated over many years of developing human sensory organ pharmaceutical products in the development and promotion of animal pharmaceutical products and other animal products, helping our pets to live long and happy lives.







**Senju Pharmaceutical Co., Ltd.**

2-5-8, Hirano-machi, Chuo-ku, Osaka

TEL : 06-6201-2512 (main switchboard)

FAX : 06-6226-0406

URL : <http://www.senju.co.jp>

# Milestones in Our History

1947	April	The Company founded at 12-Ishigatsuji-cho, Tennoji-ku, Osaka. Start-up capital of 195,000 yen. President, Hiroshi Tsuzuki.
	July	Injection Product for Neutropenia, "PANILTIN", launched.
1949	February	Reishin Tanimura becomes the President of the Company.
	September	Company head office relocated to 2-42 Hirano-machi, Higashi-ku, Osaka.
	September	Manufacturing plant relocated to 482 Iwazono-cho, Ashiya City.
1951	June	Agreement concluded with Takeda Pharmaceutical Company Limited for the sole distribution of Senju Products.
1953	October	Capital increased to 780,000 yen.
1955	December	Masao Yoshida becomes the President of the Company.
1957	March	Capital increased to 3,000,000 yen.
	April	Tokyo Branch opened.
1958	December	Ophthalmic Solution for Cataracts, "CATALIN", launched.
1960	August	Capital increased to 6,000,000 yen.
	November	Implementation of the City Planning Act meant the company relocated the Ashiya Plant to a newly-built plant at 416 Iwazono-cho.
1961	April	Fukuoka Branch opened.
	May	Capital increased to 9,000,000 yen.
1962	August	Capital increased to 13,500,000 yen.
	December	Itami Plant newly built for the manufacture of ingredients at 1-1 Oshika-Sakuragaoka, Itami City.
1963	May	Capital increased to 18,000,000 yen.
	September	Laboratory and attached facilities newly built at the Ashiya Plant.
1964	May	Capital increased to 30,000,000 yen.
1965	April	Artificial Tear Ophthalmic Solutions, "MYTEAR", launched.
	May	Company head office relocated to 1-83 Doshin-cho, Kita-ku, Osaka.
1967	September	Nagoya Branch opened.
1969	November	Capital increased to 75,000,000 yen.
1970	April	Sendai Branch opened.
1971	July	Sapporo Branch opened.
	October	Laboratory completed in the Itami Plant.
1972	March	Company head office and Osaka Branch relocated to 3-28 Hirano-machi, Higashi-ku, Osaka (Amakasu Building).
1973	April	Hiroshima Branch opened.
	April	Capital increased to 150,000,000 yen.
1974	June	Manufacturing Plant Fukusaki built at 767-7 Kazukanonishi, Saiji, Fukusaki-cho, Kanzaki-gun, Hyogo.
1975	October	Capital increased to 225,000,000 yen.
1978	June	Shoji Yoshida becomes the President of the Company.
	November	Company head office relocated to 3-6-1 Hirano-machi, Higashi-ku, Osaka (7 <sup>th</sup> Floor of Hirano-machi Century Building).
1980	February	Ophthalmic Solution for use on contact lens, "MYTEAR CL", launched.
1981	April	Capital increased to 450,000,000 yen.
1983	June	A biological laboratory completed in the Itami Research Laboratory.
1984	September	Capital increased to 1,050,000,000 yen.
	October	Utsunomiya Branch, Matsumoto Branch, and Takamatsu Branch opened.
1985	April	Kyoto Branch opened.
1987	January	Intraocular Irrigating Solution, "OPEGUARD MA", launched.
	June	Capital increased to 1,415,500,000 yen.
	October	NSAID Ophthalmic Solution, "NIFLAN", launched.
1993	January	Los Angeles Office opened in USA.
	February	Kobe Creative Center completed.
	May	Yokohama Branch opened.
1994	June	Kobe Branch opened.
1999	April	Chiba Branch and Saitama Branch opened.
2000	July	NSAID Ophthalmic Solution, "BRONUICK", launched.
2001	April	A laboratory completed in Oregon, USA.
2004	April	The European Office opened.
2006	April	Beijing Office opened in China.
	April	Senju USA, Inc. established.
	April	Senju Laboratory of Ocular Science, Kobe Laboratory completed.
	June	Yukoh Yoshida becomes the President of the Company.
2008	May	Senju Medical Consulting (Shanghai) Co., Ltd. established in Shanghai, China.
	August	Osaka Logistical Warehouse opened.
	December	Manufacturing Plant Karatsu built at 4228-1 Ishishi, Karatsu-shi, Saga.
2009	October	Ophthalmic Solution for Glaucoma Ocular Hypertension, "LUMIGAN", launched.
2010	November	Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd. established.
2011	December	Hanoi Office opened in Hanoi, Vietnam.
2012	May	Ophthalmic Solution for Glaucoma Ocular Hypertension, "AIPHAGAN", launched.
	December	Moscow Office opened in Moscow, Russia.
2013	August	Saitama Office opened.
2014	January	Chiba Office opened.
	March	Shizuoka Satellite Office opened.
	July	Senju Wanhe Pharmaceutical Shenzhen Corp. established in Shenzhen, China as a joint company.

# Company Profile

Trade Name Senju Pharmaceutical Co., Ltd.  
 Principal Office 2-5-8, Hirano-machi, Chuo-ku, Osaka, 541-0046, Japan  
 TEL: +81-6-6201-2512  
 FAX: +81-6-6226-0406

Date of Incorporation April, 1947  
 Representative Yukoh Yoshida  
 Capital 1.4 billion yen  
 Employees 861 (as of March 2015)  
 Sales 35 billion yen (as of March 2015)  
 Accounting Period March  
 Business Content (1) Pharmaceutical business: manufacture and sale of prescription eye, ear, nose and throat medicines, contact lens solutions and animal medicines  
 (2) Other business: manufacture and sale of raw materials for cosmetics



## Matters related to officers


### Member of the Board of Directors

Shoji Yoshida Chairman of the Board  
 Yukoh Yoshida President & CEO  
 Shuhei Yoshida Executive Vice President & COO  
 Head of Corporate Management Division and Business Strategy Division  
 Mitsuyoshi Azuma Managing Executive Officer  
 Head of Laboratory, Senju Laboratory of Ocular Science  
 Takashi Masuda Managing Executive Officer  
 Head of Pharmaceutical Marketing Division  
 Akemi Yamasaki Corporate Auditor

### Executive Officer

Takeshi Sugisawa Head of Business Development Division  
 Hidemi Shimoji Head of Research and Development Division  
 Mikio Ogawa Head of Overseas Business Division  
 Tomio Maenaka Head of Production Division  
 Michinari Wada Head of Reliability Assurance Division  
 Takahiro Ogawa President of SENJU USA (secondment)

## Trends in Sales and Current Profits



	2010	2011	2012	2013	2014
Sales	23.6	25.1	28.6	33.0	35.0
Current profits	3.0	4.4	2.6	5.1	7.4

Unit: Billion yen

# Offices (Overseas)

---

---

## Laboratories and Offices

---

### ● SENJU LABORATORY OF OCULAR SCIENCES (SLOS)

OTRADI Bioscience Incubator, 4640 SW Macadam Ave., Suite 200C, Portland, OR 97239, U.S.A.

Tel: +1-503-748-5202

Fax: +1-503-748-5204

### ● SENJU PHARMACEUTICAL CO., LTD. BEIJING OFFICE

Unit 3602, Fortune Plaza Office Tower A, No. 7 Dongsanhuan Zhonglu, Chaoyang District, Beijing, 100020 P.R.C

Tel: +86-10-6533-0200

Fax: +86-10-6536-1329

### ● SENJU PHARMACEUTICAL CO., LTD. Hanoi Representative Office

Room 1314, Level 13, Ha Noi Towers, 49 Hai Ba Trung, Hoan Kiem District, Ha Noi, Vietnam

Tel: +84-4-3934-3890

Fax: +84-4-3934-3966

### ● Moscow Representative Office of Senju Pharmaceutical Co., Ltd.

Office No.105, 1st floor, str. 6, dom 1A, Tretiy Nizhnelikhoborskiy proyezd, Moscow 125371, Russian Federation

## Subsidiaries

---

### ● SENJU USA, INC.

21700 Oxnard Street, Suite 1070 Woodland Hills, CA 91367, U.S.A.

Tel: +1-818-719-7190

Fax: +1-818-719-7195

### ● SENJU PHARMACEUTICAL SCIENCE & TECHNOLOGY (BEIJING) CO., LTD.

Unit 3602, Fortune Plaza Office Tower A, No. 7 Dongsanhuan Zhonglu, Chaoyang District, Beijing, 100020 P.R.C

Tel: +86-10-6533-0200

Fax: +86-10-6536-1329

### ● SENJU WANHE PHARMACEUTICAL (SHENZHEN) CO., LTD.

Block B, Wanhe Technology Complex, Hi-tech Park, Guangming District, Shenzhen, Guangdong Province, China



# Offices (Japan)



## Head Office

Hirano-machi Century Building  
2-5-8, Hirano-machi, Chuo-ku, Osaka, 541-0046  
TEL: +81-6-6201-2512 (main switchboard) FAX: +81-6-6226-0406

## Branches and Groups

### [Northern Japan Branch]

● **Sapporo Office, Sapporo Group**  
Takeda Sapporo Building,  
13-4, Kitaichijonishi, Chuo-ku, Sapporo-shi, Hokkaido, 060-0001  
TEL: +81-11-221-2743

● **Sendai Office, Tohoku First Group, Tohoku Second Group**  
Takeda Sendai Building  
2-18-21, Honcho, Aoba-ku, Sendai-shi, Miyagi, 980-0014  
TEL: +81-22-264-2288

### [Saitama Kitakanto Shinetsu Branch]

● **Utsunomiya Office, Kita-Kanto Group**  
Chuo Utsunomiya Building  
3-1-1, Higashishukugo, Utsunomiya-shi, Tochigi, 321-0953  
TEL: +81-28-633-6250

● **Saitama Office, Saitama Group, Shinetsu Group**  
82 Omiya Building  
1-11-3, Sakuragicho, Omiya-ku, Saitama-shi, Saitama, 330-0854  
TEL: +81-48-658-2340

### [Kanto Branch]

● **Chiba Office, Chiba Group**  
Lalaport Mitsui Building  
2-1-1, Hamacho, Funabashi-shi, Chiba, 273-0012  
TEL: +81-47-431-1238

● **Tokyo Office, Tokyo First Group, Tokyo Second Group, Tokyo Third Group**  
MFPR Nihonbashihoncho Building  
3-7-2, Nihonbashihoncho, Chuo-ku, Tokyo, 103-0023  
TEL: +81-3-5643-1950

● **Yokohama Office, Yokohama Group**  
Higashitotsuka West Building  
90-6, Kawakamicho, Totsuka-ku, Yokohama-shi, Kanagawa, 244-0805  
TEL: +81-45-828-1381

### [Tokai Branch]

● **Nagoya Office, Tokai First Group, Tokai Second Group**  
Nishiki Park Building  
2-4-3, Nishiki, Naka-ku, Nagoya-shi, Aichi, 460-0003  
TEL: +81-52-211-2560

● **Shizuoka Satellite Office, Tokai First Group (Shizuoka base)**  
Mitsui Seimei Shizuoka-ekimae Building  
11-7, Kuroganecho, Aoi-ku, Shizuoka-shi, Shizuoka, 420-0851  
TEL: +81-52-211-2560 (Nagoya Office)

### [Kansai Shikoku Branch]

● **Kyoto Office, Kyoto Group**  
Sumitomo Seimei Kyoto Building  
62, Tsukihokocho, Shinmachihigashiiru, Shijodori,  
Shimogyo-ku, Kyoto-shi, Kyoto, 600-8492  
TEL: +81-75-229-6549

● **Osaka Office, Osaka First Group, Osaka Second Group**  
Takeda Hirano-machi Building  
2-4-9, Hirano-machi, Chuo-ku, Osaka, 541-0046  
TEL: +81-6-6226-0403

● **Kobe Office, Kobe Group**  
Kobe Itomachi Building  
121, Itomachi, Chuo-ku, Kobe-shi, Hyogo, 650-0032  
TEL: +81-78-321-0475

● **Takamatsu Office, Shikoku Group**  
Takamatsu Daiichi Seimei Building  
1-3-2, Kotobukicho, Takamatsu-shi, Kagawa, 760-0023  
TEL: +81-87-822-9492

### [Kyushu Chugoku Branch]

● **Hiroshima Office, Chugoku Group**  
Takeda Hiroshima Building  
1-25, Komachi, Naka-ku, Hiroshima-shi, Hiroshima, 730-0041  
TEL: +81-82-248-2023

● **Fukuoka Office, Kyushu First Group, Kyushu Second Group**  
Fukuoka Takeda Building  
9-12, Shimokawabatamachi, Hakata-ku, Fukuoka-shi, Fukuoka, 812-0027  
TEL: +81-92-271-2390

## Manufacturing Plants and Research Laboratories

● **Manufacturing Plant Karatsu**  
4228-1, Ishishi, Karatsu-shi, Saga, 847-0832  
TEL: +81-955-78-1050

● **Manufacturing Plant Fukusaki**  
767-7, Saiji, Fukusakicho, Kanzaki-gun, Hyogo, 679-2285  
TEL: +81-790-22-2671

● **Kobe Creative Center**  
1-5-4, Murotani, Nishi-ku, Kobe-shi, Hyogo, 651-2241  
TEL: +81-78-997-1010

● **Senju Laboratory of Ocular Science**  
BMA  
1-5-5, Minatojiminamimachi, Chuo-ku, Kobe-shi, Hyogo, 650-0047  
TEL: +81-78-303-4031



# Products (Overseas)

## Asia

### China

- ◇Pranopulin (Senju)
- Catalin (Senju)
- Bronuck (Senju)
- ◎Sodium Hyaluronate (Senju)
- ★Talymus (Senju)

### Hong Kong

- Catalin (Takeda Hong Kong)

### South Korea

- ◇Pranopulin (JW Shinyak)
- ☆Lomeflon (JW Shinyak)
- Timobetalol-LA (Taejoon)
- Bronuck (Taejoon)
- Senju CL (JW Pharma)
- Frenz Eye Drops (JW Pharma)

### Taiwan

- Catalin K (Takeda Taiwan)

### Philippines

- Catalin (Takeda Philippines)

### Thailand

- Catalin (Takeda Thailand)

### Vietnam

- Bronuck (Senju)
- ◎Tearbalance (Senju)

### Indonesia

- Catalin (P.T. Takeda Indonesia)

### Pakistan

- Catalin (Helix)

### India

- GlucotimLA (Centaur)
- Ocubro (Centaur)

## Americas

### United States

- Istalol (B+L)
- Prolensa (B+L)
- Bromday (B+L)
- Bepreve (B+L)
- Durezol (Alcon)

### Mexico

- ◇Niflan (SIFI)

### Brazil

- Clarvisol (Allergan)

### Puerto Rico

- Durezol (Alcon)

### Canada

- Durezol (Alcon)

## Europe and the Middle East

### Poland

- Catalin (Pharmaheads)
- Yellox (Valeant)

### Romania

- ◇Pranoflog (SIFI)

### Belgium

- ◇Pranox (MEDA)

### Portugal

- Clarvisan (LUSO)
- Yellox (Valeant)

### Italy

- Clarvisan (Allergan)
- ◇Pranoflog (SIFI)
- Yellox (Valeant)

### Russia

- Catalin (Senju)

### Germany

- Yellox (Valeant)

### United Kingdom

- Yellox (Valeant)

### Austria

- Yellox (Valeant)

### France

- Yellox (Valeant)

### Netherlands

- Yellox (Valeant)

### Republic of Ireland

- Yellox (Valeant)

### Sweden

- Yellox (Valeant)

### Norway

- Yellox (Valeant)

### Denmark

- Yellox (Valeant)

### Finland

- Yellox (Valeant)

### Spain

- Yellox (Valeant)

### Bulgaria

- Yellox (Valeant)

### Hungary

- Yellox (Valeant)

### Switzerland

- Yellox (Valeant)

### Saudi Arabia

- Catalin (Saudi Arabian Drug Store)

Product names in Japan: ● CATALIN ☆ LOMEFLON ◇ NIFLAN □ BRONUCK ◎ TEARBALANCE ★ TALYMUS ■ Generic medicine ○ Not sold in Japan  
 \*( )=Marketing Authorization Holder

As of July 2015

# Products (Japan)

## Prescription Products

### [Eye products]

#### ■ Inflammation and allergy

ELICS OPHTHALMIC SOLUTION 0.25%  
ODOMEL OPHTHALMIC SOLUTION 0.02%  
ODOMEL OPHTHALMIC SOLUTION 0.05%  
ODOMEL OPHTHALMIC SOLUTION 0.1%  
CROMOFERON OPHTHALMIC SOLUTION 2%  
KETAS OPHTHALMIC SOLUTION 0.01%  
NIFLAN OPHTHALMIC SOLUTION 0.1%  
VISUALIN OPHTHALMIC SOLUTION 0.02%  
VISUALIN OPHTHALMIC SOLUTION 0.05%  
VISUALIN SOLUTION FOR EYE EAR AND NOSE 0.1%  
BRONUCK OPHTHALMIC SOLUTION 0.1%  
LYSOTEAR OPHTHALMIC SOLUTION 0.5%  
LEVOCABASTINE 0.025% OPHTHALMIC SOLUTION [TS]

#### ■ Antibacterial and antifungal agents

GATIFLO OPHTHALMIC SOLUTION 0.3%  
BACCIDAL OPHTHALMIC SOLUTION 0.3%  
PIMARICIN 1% Ointment [SENJU]  
PIMARICIN OPHTHALMIC SOLUTION 5% [SENJU]  
BESTRON OPHTHALMIC SOLUTION 0.5%  
LOMEFLON OPHTHALMIC SOLUTION 0.3%  
LOMEFLON MINIMS SOLUTION FOR EYE AND EAR 0.3%

#### ■ Cataracts

CATALIN FOR OPHTHALMIC 0.005%  
CATALIN-K FOR OPHTHALMIC 0.005%

#### ■ Glaucoma

AIPHAGAN OPHTHALMIC SOLUTION 0.1%  
MIKELAN OPHTHALMIC SOLUTION 1%  
MIKELAN OPHTHALMIC SOLUTION 2%  
MIKELAN LA OPHTHALMIC SOLUTION 1%  
MIKELAN LA OPHTHALMIC SOLUTION 2%  
LATANOPROST OPHTHALMIC SOLUTION 0.005% SENJU  
LUMIGAN OPHTHALMIC SOLUTION 0.03%

#### ■ Surgical aids

INDOMELOL OPHTHALMIC SOLUTION 0.5%  
OXYBUPROCAINE HYDROCHLORIDE MINIMS OPHTHALMIC SOLUTION 0.4% [SENJU]  
OPEGUARD-MA INTRAOCULAR IRRIGATING SOLUTION  
OPEGUARD Neo Kit INTRAOCULAR IRRIGATING SOLUTION 0.0184%  
OPELEAD 0.5 OPHTHALMIC VISCOELASTIC PREPARATION 1%  
OPELEAD 0.6 OPHTHALMIC VISCOELASTIC PREPARATION 1%  
OPELEAD 1.1 OPHTHALMIC VISCOELASTIC PREPARATION 1%  
OPELEAD HV0.4 OPHTHALMIC VISCOELASTIC PREPARATION 1%  
OPELEAD HV0.6 OPHTHALMIC VISCOELASTIC PREPARATION 1%  
OPELEAD HV0.85 OPHTHALMIC VISCOELASTIC PREPARATION 1%

#### ■ Other

ARTIFICIAL TEAR MYTEAR OPHTHALMIC SOLUTION  
SCOPISOL SOLUTION FOR EYE  
SOFTEAR OPHTHALMIC SOLUTION 0.02%  
TAZIN TABLETS 30  
TALYMUS OPHTHALMIC SUSPENSION 0.1%  
TEARBALANCE OPHTHALMIC SOLUTION 0.1%  
TEARBALANCE OPHTHALMIC SOLUTION 0.3%  
TEARBALANCE MINIMS OPHTHALMIC SOLUTION 0.3%

### [Ear, nose and throat products]

VISUALIN SOLUTION FOR EYE EAR AND NOZE 0.1%  
BESTRON FOR EAR AND NOSE 1%  
LOMEFLON SOLUTION FOR EAR 0.3%  
LOMEFLON MINIMS SOLUTION FOR EYE AND EAR 0.3%

## Over the Counter (OTC) Products

#### ■ Eye medicine

Mytear EYETECT  
Mytear EYETECT ALPITATTO  
Mytear EYETECT ALPITATTO-N  
Mytear ALPITATTO EX $\alpha$   
Mytear ALPITATTO N EX $\alpha$   
NewMytear A  
MytearClean Cool  
Mytear Vitamin B<sub>2</sub>B<sub>6</sub>E  
Mytear Vido  
Mytear Fresh40

#### ■ Eye medicine for use with contact lens

NewMytear CL a  
NewMytear CL Cool a  
NewMytear CL Cool Hi a  
NewMytear CL Ice Crush  
FirstMytear CL-P  
FirstMytear CL-G  
FirstMytear CL-B

## Contact Lens Products

#### ■ O<sub>2</sub>/hard use

Mytear Hard Lens Wearing Solution (designated quasi-drug)  
NewMytear Easy S  
NewMytear CL O<sub>2</sub> Lens Care

## Animal Medicines

STEROP  
TEAROSE  
PAPITEIN  
MIMIENA  
LIGHT CLEAN  
LOMEWON  
ONE CLEAN

## Animal Quasi-Drugs

BEST FRIENDS EAR CLEANER A  
BEST FRIENDS EAR CLEANER G

## Animal Health Products

BEST FRIENDS RINSE IN SHAMPOO  
BEST FRIENDS TREATMENT MIST TYPE